OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CHEM56

Chembond Material Technologies Ltd

Specialty ChemicalsVerified

Chembond's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. The company's liquidity position is moderate, with a current ratio of 2.23, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow of INR 111.33 million supports operational flexibility, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity (ROE) of 11.25% and a return on assets (ROA) of 8.71%, both above the industry median for Specialty Chemicals. These figures suggest Chembond is generating returns in line with or better than its peers, though the operating margin of 6.3% (calculated from operating income of INR 127.11 million on revenue of INR 2.01 billion) is a key area to monitor for sustainability. The company operates in two segments: Specialty Chemical and Animal Health. Revenue concentration data is not explicitly provided, but the dual-segment structure implies diversification. The Animal Health segment is likely to benefit from growing demand in the livestock and aquaculture industries, while the Specialty Chemical segment is exposed to broader industrial and consumer markets. Growth trajectory is modest, with no explicit guidance provided for the current or next fiscal year. Historical revenue of INR 2.01 billion provides a baseline, but without forward-looking revenue deltas, it is difficult to assess acceleration or deceleration in growth. The company's capital expenditure of INR -43.71 million suggests a focus on cost optimization rather than expansion. Risk factors include moderate liquidity risk, as the company has negative net cash after subtracting total debt. Dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. However, the absence of a detailed capital allocation strategy in the input data limits visibility on long-term risk mitigation. Recent events are not explicitly detailed in the input data, but the company's financial snapshot and risk assessment suggest a stable but cautious operational environment. No major regulatory or geopolitical events are cited in the input, though the company's exposure to the Indian market may introduce macroeconomic volatility.

30-day price · CHEM+55.76 (+45.7%)
Low$105.20High$205.78Close$177.86As of17 May, 00:00 UTC
Profile
CompanyChembond Material Technologies Ltd
TickerCHEM.NS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Chembond Material Technologies Limited is engaged in the manufacture of specialty chemicals, vitamins and minerals, probiotic and prebiotic enzymes, as well as feed additives and nutrition products related to animal health.

Classification. Chembond is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with a confidence level of 0.92.

Chembond's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. The company's liquidity position is moderate, with a current ratio of 2.23, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow of INR 111.33 million supports operational flexibility, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity (ROE) of 11.25% and a return on assets (ROA) of 8.71%, both above the industry median for Specialty Chemicals. These figures suggest Chembond is generating returns in line with or better than its peers, though the operating margin of 6.3% (calculated from operating income of INR 127.11 million on revenue of INR 2.01 billion) is a key area to monitor for sustainability. The company operates in two segments: Specialty Chemical and Animal Health. Revenue concentration data is not explicitly provided, but the dual-segment structure implies diversification. The Animal Health segment is likely to benefit from growing demand in the livestock and aquaculture industries, while the Specialty Chemical segment is exposed to broader industrial and consumer markets. Growth trajectory is modest, with no explicit guidance provided for the current or next fiscal year. Historical revenue of INR 2.01 billion provides a baseline, but without forward-looking revenue deltas, it is difficult to assess acceleration or deceleration in growth. The company's capital expenditure of INR -43.71 million suggests a focus on cost optimization rather than expansion. Risk factors include moderate liquidity risk, as the company has negative net cash after subtracting total debt. Dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. However, the absence of a detailed capital allocation strategy in the input data limits visibility on long-term risk mitigation. Recent events are not explicitly detailed in the input data, but the company's financial snapshot and risk assessment suggest a stable but cautious operational environment. No major regulatory or geopolitical events are cited in the input, though the company's exposure to the Indian market may introduce macroeconomic volatility.
Key takeaways
  • Chembond maintains a conservative capital structure with a low debt-to-equity ratio of 0.02.
  • ROE of 11.25% and ROA of 8.71% indicate strong profitability relative to industry norms.
  • The company's dual-segment structure (Specialty Chemical and Animal Health) provides diversification.
  • Free cash flow of INR 111.33 million supports operational flexibility but is offset by negative net cash.
  • Growth trajectory is unclear without forward-looking revenue guidance, and capital expenditure is negative, suggesting a focus on cost control.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUnknown error in universe processing
Revenue$2.01B
Gross profit$767.2M
Operating income$127.1M
Net income$175.6M
R&D
SG&A
D&A
SBC
Operating cash flow$194.8M
CapEx-$43.7M
Free cash flow$111.3M
Total assets$2.02B
Total liabilities$455.7M
Total equity$1.56B
Cash & equivalents
Long-term debt$26.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.56B
Net cash-$26.5M
Current ratio2.2
Debt/Equity0.0
ROA8.7%
ROE11.2%
Cash conversion1.1%
CapEx/Revenue-2.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricCHEMActivity
Op margin6.3%0.4% medp25 -8.0% · p75 16.0%above median
Net margin8.7%2.3% medp25 -11.6% · p75 11.8%above median
Gross margin38.1%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-2.2%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity2.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-03 23:30 UTC#b2d57c87
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 23:32 UTCJob: 964592d4